PBLA Panbela Therapeutics Dashboard

Sun BioPharma Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Company profile

Ticker

PBLA

Exchange

NASDAQ

Website

www.sunbiopharma.com/

CEO

Michael Cullen

Incorporated

Delaware

Location

Minnesota

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Computer Systems Design Services

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.

SEC CIK

0001029125

Corporate docs

Articles of Incorporation & Bylaws

PBLA stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

12 Health Care Stocks Moving In Thursday's Pre-Market Session

15 Apr 21

Panbela Announces Partial Clinical Hold Lifted On Phase I Polyamine Metabolic Inhibitor Study In Pancreatic Cancer

15 Apr 21

Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the U.S. Food and Drug Administration

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

13 Apr 21

Panbela Therapeutics Announces Poster Presentation At American Society Of Clinical Oncology Annual Meeting Jul. 4-8

6 Apr 21

12 Health Care Stocks Moving In Friday's Pre-Market Session

26 Mar 21

Press releases

Pro users get this 30m faster

Panbela Announces Partial Clinical Hold Lifted on Phase I Polyamine Metabolic Inhibitor Study in Pancreatic Cancer

15 Apr 21

MINNEAPOLIS, April 15, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

6 Apr 21

MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today

Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

26 Mar 21

MINNEAPOLIS, March 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share reported in the

Panbela Therapeutics, Inc. to Host Earnings Call

25 Mar 21

Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

25 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

24 Mar 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart PBLA financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	9.02M	9.02M	9.02M	9.02M	9.02M	9.02M
Cash burn (monthly)	616K	(positive/no burn)	533.67K	480.58K	371K	321.17K
Cash used (since last report)	2.2M	n/a	1.9M	1.71M	1.32M	1.15M
Cash remaining	6.82M	n/a	7.12M	7.31M	7.7M	7.88M
Runway (months of cash)	11.1	n/a	13.3	15.2	20.8	24.5

Beta Read what these cash burn values mean

Recent insider trades

PBLA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Mar 21	Michael T. Cullen	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.09	55,000	224.95K	55,000
30 Mar 21	Gagnon Suzanne	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.09	35,000	143.15K	35,000
30 Mar 21	Simpson Jennifer K.	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.09	170,000	695.3K	170,000
30 Mar 21	Horvath Susan	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.09	40,000	163.6K	40,000
1 Dec 20	Fratamico Arthur	Common Stock	Grant	Aquire A	No	No	0	2,875	0	5,299

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

PBLA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	6	EXIT
Opened positions	0	5	EXIT
Closed positions	5	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	1.02M	EXIT
Total shares	0	340.12K	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change
Worth Venture Partners	0	-123.64K	EXIT
CVI	0	-79.03K	EXIT
Essex Investment Management	0	-76.77K	EXIT
Verition Fund Management	0	-60.61K	EXIT
Tower Research Capital	0	-81	EXIT
Proequities	0	0

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Advisor, affiliate, agriculture, Allergan, alleviate, analyzed, arose, background, Bekaert, biotech, Bloomington, Blvd, Boston, Casero, category, Cerecor, chair, Champion, Chapter, character, checkpoint, Cherry, combat, composed, conference, conferred, conflict, consummated, corn, counter, County, CRNP, cut, cutoff, deal, dealing, decade, decentralized, dedicated, Delcath, depletion, dismutase, distressed, Drexel, Eagle, elevated, Eli, eNeura, eye, farming, fiduciary, forgiven, Galera, Garry, Gemin, Gemphire, graduate, graduated, headcount, Heart, higher, highest, ImClone, immune, immunology, indirect, inhibitory, innovative, inquired, insight, insulate, interference, interrupted, Janssen, jennifer, Kandiyohi, launch, leadership, learn, lesser, lifted, Lilly, literacy, logical, Lycera, Madeline, matter, microenvironment, mid, migraine, month, mother, MSN, nephrology, neurological, NeuroOne, nominating, nurse, Ortho, overseen, owner, panbela, pause, paused, Paycheck, payroll, PBLA, petition, pharmacist, PharmD, Phenix, Philadelphia, poster, PPP, practitioner, pre, prorated, prospective, pure, radiologic, radiotherapy, Ramucirumab, ratified, ratify, rational, raw, reauthorized, recondition, recuse, rent, reopen, resourcing, restarted, retrospective, SBR, serial, settlement, Shaffer, simpson, Society, spouse, spring, staffing, Subtopic, sugar, Teewinot, transformed, transforming, ValAdCo, visual, Vitae, VStock, wage, wealth, yearend

Removed: acid, adjuvant, allocate, analyst, announced, Appointment, ASC, bid, borrowed, bought, broker, buy, cancelled, categorized, closing, complied, contested, core, deemed, deficit, delaying, denied, deterring, digestive, diminish, direction, domestic, efficiently, enterprise, exchanged, exemption, expanding, explored, feel, folic, formation, formulate, frame, hire, holder, incorporate, inefficiency, influencing, intangible, joint, licensor, liquid, mature, maturity, media, minimal, movement, occurrence, optimally, organized, partnership, penny, possession, proposal, quotation, representing, resell, retail, revised, safely, secondary, segment, Similarly, standardized, stringent, supervise, tangible, train, unaffected, unamortized, understood, unpaid, venture, volatile

From filing 10-K 2020 FY